

[CANCER RESEARCH 58, 3905-3908, September 1, 1998]

Chimeric Human-Mouse IgG Antibodies with Shuffled Constant Region Exons Demonstrate that Multiple Domains Contribute to *in Vivo* Half-Life

Lionel S. Zuckier,¹ Chee J. Chang, Matthew D. Scharff, and Sherie L. Morrison

Departments of Nuclear Medicine (L. S. Z.), Epidemiology and Biostatistics (C. J. C.), and Cell Biology (M. D. S.), Albert Einstein College of Medicine, Bronx, New York 10461, and Department of Microbiology and Molecular Genetics and the Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California 90095 (S. L. M.)

ABSTRACT

Structural features that determine the differing rates of immunoglobulin catabolism are of great relevance to the engineering of immunologically active reagents. Sequences in the C_H2 and C_H3 region of IgG have been shown to regulate the rate of clearance through their interaction with FcRn. In an attempt to probe additional structural features that regulate antibody half-life, we have investigated two families of chimeric antibodies, composed of identical murine heavy and light antidiarrheal variable regions joined to human κ light-chains and wild-type or shuffled human IgG heavy-chain constant regions. These antibodies were iodinated, and their clearance was studied in severe combined immunodeficient mice hosts by whole-body radioactivity measurements. Clearances of the wild-type and recombinant antibodies were biphasic. In a panel of immunoglobulins derived from IgG₂ and IgG₃, as successive domains were varied from γ_2 to γ_3 , β -phase half-life gradually decreased from 337.0 h to 70.6 h. Statistical analysis suggested that the composition of each of the three domains affected half-life, and no single region of the molecule by itself determined the rate of clearance. In the second panel of immunoglobulins derived from IgG₁ and IgG₄, the construct with the amino terminus portion of the molecule derived from IgG₄, joined within the C_H2 domain to the COOH terminus portion of IgG₁, had a half-life paradoxically greater than either IgG₁ or IgG₄ ($P < 0.012$). All four IgG₁/IgG₄ constructs demonstrated presence of the concentration catabolism phenomenon, which is a unique hallmark of immunoglobulin catabolism. The contribution of all three constant region domains to immunoglobulin half-life may be due to distant conformational effects in addition to direct binding to protective receptors, and emphasizes the importance of distant sequences on the rate of immunoglobulin catabolism. Interesting possibilities regarding mechanisms controlling immunoglobulin metabolism are raised by the hybrid γ_4/γ_1 molecule with a half-life greater than either parental immunoglobulin. Understanding the relationships between the structure of these molecules and their clearance rate will further our ability to produce immunoglobulins with improved pharmacokinetic properties.

INTRODUCTION

Over the last 2 decades, the concept of immunologically-targeted diagnostic and therapeutic agents has advanced from a laboratory curiosity to human clinical trials and ultimately to U. S. F. D. A. approval, in selected instances (1). Four radiolabeled murine monoclonal antibodies are presently approved for human diagnostic use, and a number of other immunological agents are in the developmental process for diagnostic and therapeutic applications (1, 2). A limitation of many of these reagents is that they contain at least portions of murine immunoglobulins, which can lead to the production of human antimouse antibodies, affecting subsequent biodistribution (3) and potentially interfering with antigen binding. For this reason, recombinant DNA techniques have been applied to redesign these foreign antibody molecules, making them more human-like, by "chimeriza-

tion" (4) or "humanization" (3, 5, 6). Antibody constant-region structure also determines the rate of intravascular clearance, which is a crucial variable in pharmacokinetics of antibody delivery. Modification of half-life by antibody engineering has not been as greatly explored, in part because the molecular structures that control immunoglobulin homeostasis have only recently begun to be elucidated in detail (7-9).

From an experimental point of view, a study of the regulation of metabolism of human antibodies would be most naturally examined in man; however, relevant studies cannot be easily performed in human subjects due to ethical and safety concerns, and animal investigation must instead represent the initial mode of study. We have previously reported on a model system (10) for studying the half-life of iodinated chimeric antibodies in SCID mice (11) that lack a "mouse antihuman antibody" response. Four chimeric proteins were studied, composed of identical murine antidiarrheal variable regions and human κ light-chains and IgG heavy-chains. Whole-body half-lives for IgG₁₋₄ were determined to be 170.0 ± 15.5 , 312.3 ± 30.8 , 59.8 ± 4.18 , and 71.0 ± 3.34 h, respectively, and the concentration-catabolism phenomenon, a hallmark of normal IgG catabolism (12, 13), was preserved. In this model system, the terminal or β phase of whole-body half-life was statistically indistinguishable from that of intravascular half-life (10). In an attempt to probe the structural correlates of antibody catabolism, we now extend our observations to include chimeric antibodies with successively shuffled or otherwise rearranged human constant regions, which have been useful tools in elucidating the structural basis of other immunoglobulin properties (14, 15).

MATERIALS AND METHODS

Immunoglobulins. Two panels of immunoglobulins were studied. γ_2/γ_3 constructs derived from portions of the IgG₂ and IgG₃ molecule and γ_1/γ_4 constructs derived from IgG₁ and IgG₄ (Table 1). These recombinant immunoglobulins are composed of identical murine heavy and light antidiarrheal variable regions joined to human κ light-chains and wild-type or recombinant human IgG heavy-chain constant regions. Construction and expression of the immunoglobulins has been described previously (15). In the γ_2/γ_3 constructs, the heavy-chain constant region domains are positioned appropriately within the immunoglobulin molecule, but derive variably from either γ_2 or γ_3 . In this panel, the hinge region always originates from the same isotype as the C_H1 domain, resulting in eight possible permutations of the heavy-chain constant region domains, of which six were available for analysis in the present study. The second panel of recombinant γ_1/γ_4 constructs is composed of shuffled IgG₁ and IgG₄ constant-region domains, with DNA rearrangement performed in the mid-C_H2 domain sequences, resulting in a total of four permutations (Table 1).

Proteins were gently iodinated with ¹²⁵I by the Iodogen (Pierce Chemical Co., Rockford, IL) method (16) to a specific activity of approximately 1-2 μ Ci/ μ g as described previously (10). Free iodine was separated from the iodinated proteins by passage over a size exclusion column (Sephadex G-25; Pharmacia Fine Chemicals, Piscataway, NJ).

Animals. Adult SCID² mice were used to study half-life, according to our previously described model (10). Thyroid uptake of radioiodine was blocked

Received 9/26/97; accepted 7/2/98.

The cost of publication of this article was defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom requests for reprints should be addressed, at Department of Nuclear Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 121, Bronx, NY 10461.

² The abbreviation used is SCID, severe combined immunodeficient.

HALF-LIFE OF CHIMERIC ANTIBODIES

Table 1 Composition and half-life of wild-type and recombinant immunoglobulins β -phase whole-body half-life (mean \pm S.D.) for two families of iodinated recombinant human immunoglobulin constructs, injected intravenously into SCID mice.

Family	Composition				Name	Half-life (h)
	C _{H1}	Hinge	C _{H2}	C _{H3}		
γ_2/γ_3	2	2	2	2	IgG ₂	337.0 \pm 13.7
	2	2	3	2		292.6 \pm 21.9
	2	2	2	3		195.5 \pm 6.2
	3	3	2	3		128.1 \pm 3.2
	3	3	3	2		102.6 \pm 16.9
γ_1/γ_4	3	3	3	3	IgG ₃	70.6 \pm 2.9
	1	1	1	1		199.0 \pm 9.8
	1	1	1/4	4	IgG ₁	172.1 \pm 4.3
	4	4	4/1	1		281.5 \pm 8.2
	4	4	4	4	IgG ₄	77.3 \pm 10.1

by the addition of three drops of Strong Iodine (Lugol's) Solution U.S.P. (Regional Service Center, Inc., Woburn, MA) to the drinking water for 1 week before and during the duration of the study. Prior use of this protocol has effectively blocked thyroid uptake in clearance and imaging studies. Each of the six immunoglobulins of the γ_2/γ_3 panel were studied in three mice, whereas the four γ_1/γ_4 constructs were studied in five mice.

Whole-Body Half-Life Determination. The basic method of administration and measurement has been detailed previously (10). Each mouse received injections in the tail vein of approximately 0.1 μ Ci of activity in a volume of 0.1 ml of PBS. Whole-body retention of the radiolabeled antibodies was followed using one of two configurations of whole-body counters, in a vari-

ation of our previously described method (10). For the γ_2/γ_3 panel, counts were obtained using an early-vintage commercial whole-body animal counter (ARMAC Scintillation Detector, Packard Instruments, Downers Grove, IL), whereas for the γ_1/γ_4 constructs, a custom-designed well-type NaI scintillation detector (Wm. B. Johnson and Associates, Fairlea, WV) was interfaced to a multichannel analyzer (Packard Series 35; Packard Instruments). Whole-body measurements were taken immediately after injection of immunoglobulin, and at frequent intervals thereafter over a span of 2 weeks. At the conclusion of half-life measurements in the γ_1/γ_4 constructs, three of five mice in each of the four groups received i.p. injections of 50 mg of reconstituted human γ -globulin (Cohn Fraction II and III; Sigma Chemical Co.). An additional whole body measurement was performed 2 days thereafter, to evaluate for a change in the rate of catabolism.

Whole body measurements were corrected for background radioactivity and isotopic decay, and the retained activity was described as a percentage of that present immediately after injection. Terminal (β -phase) half-life of whole body disappearance of the labeled antibody was calculated by nonlinear regression of the data points from 2 days onward, using a commercially available pharmacokinetic software package (PCNONLIN; SCI Software, Inc., Lexington, KY), as described (10).

Tests of Statistical Significance. Because of the small sample size and variable SD, nonparametric tests were initially used. The overall effect of antibody composition on half-life was evaluated by the Kruskal-Wallis test, and pair-wise comparisons were performed using the Wilcoxon Rank-Sum test. For the panel of γ_1/γ_4 constructs, six multiple comparisons were made among the four groups, and significance was determined by comparison with the adjusted type-1 error probability. For the 15 pairwise comparisons of the




Fig. 1. Semilog plot of retained whole-body radioactivity of the recombinant antibodies expressed as the percentage of initial counts. The error bars signify one S.D. A, panel of six γ_2/γ_3 antibodies. Each point represents the mean of three mice. B, panel of four γ_1/γ_4 antibodies. Each point represents the mean of five mice, with the exception of the final points which represent the mean of three animals treated with 50 mg of human γ -globulin IP (Δ , \square , \circ , \diamond) or the mean of the two untreated animals (\bullet , \blacksquare). In all four groups, the whole-body clearance of radiolabeled antibody was accelerated in the animals administered human γ -globulin, consistent with the normally described concentration-catabolism phenomenon.

HALF-LIFE OF CHIMERIC ANTIBODIES




Fig. 2. Terminal (β) phase half-life of whole-body clearance of the iodinated antibody. A, half-life of the γ_2/γ_2 antibodies with the three animals in each group (bar). The half-life gradually decreases as the composition progressed from IgG₂ to IgG₄. B, half-life of the γ_1/γ_2 panel with each of the five animals/group (bar). Of note, the terminal half-life of the 4-4-4/1-1 recombinant molecule exceeds that of both wild-type parental immunoglobulins.

six γ_2/γ_2 constructs, the small sample size precluded attaining clear-cut significance using the highly conservative nonparametric techniques, and analysis of borderline significance was further supplemented by performing a one-way ANOVA with 15 pairwise comparisons.

RESULTS

Clearances of the wild-type and recombinant antibodies was biphasic, with a more rapid initial clearance followed by a slower subsequent rate, conforming to a model of first-order kinetics (Fig. 1, A and B). Individual β -phase half-lives are displayed in Fig. 2, A and B, and grouped statistical parameters are listed in Table 1. In the γ_2/γ_2 panel, as successive domains were varied from γ_2 to γ_3 , half-life gradually decreased from 337.0 h to 70.6 h. The overall comparison among the six groups was significant with a P of 0.0054. All of the 15 pairwise comparisons were identically significant with borderline P s of 0.0495, as compared with the adjusted P of 0.05/15. Although half-life values of animals within different groups did not overlap each other and were, therefore, maximally significant, the borderline significance was attributed to the small group size ($n = 3$) in this nonparametric test. A less conservative parametric analysis using ANOVA suggested that significant results would be obtained in larger cohorts for each of the pairwise comparisons ($P < 0.003$), with the exception of 3-3-3-2 versus either 3-3-2-3 or 3-3-3-3.

In the panel of γ_1/γ_2 constructs, the antibody with γ_4 amino terminus spliced to γ_1 COOH terminus within the C_{H2} domain (4-4-4/1-1) had a half-life of 281.5 h, greater than either parental immunoglobulin (half-lives of 199.0 and 77.3 h for IgG₁ and IgG₄, respectively), whereas the antibody with γ_1 amino terminus spliced to γ_4 COOH terminus (1-1-1/4-4) had an intermediate half-life of 172.1 h. The overall group comparison was significant ($P = 0.0005$), as

were all six pairwise comparisons relative to the adjusted type-1 error P of 0.0083 (0.05/6; $P = 0.0122$). Finally, all four IgG₁/IgG₄ constructs demonstrated presence of the concentration catabolism phenomenon, evidenced by an accelerated rate of clearance after γ -globulin administration at 15 days (Fig. 1B).

DISCUSSION

Intravascular and whole-body clearance of administered antibodies are key variables in describing pharmacokinetic behavior. Knowledge of structural features that control half-life is invaluable in designing immunological molecules for diagnostic or therapeutic human use. Despite this importance, mechanisms and structures that regulate immunoglobulin half-life have only recently begun to be elucidated (7, 8, 17-19).

An early model of IgG regulation, proposed by Brambell *et al.* (20), attempts to address the unusual concentration-catabolism phenomenon unique to IgG catabolism, whereby increasing IgG levels result in an accelerated rate of catabolism. Brambell (21) hypothesized a specific, saturable receptor for immunoglobulin, which conferred protection from degradation. The identity of such a receptor has recently been shown by several groups (17-19) to be the MHC class I-related receptor, FcRn, which binds sequences in the C_{H2} and C_{H3} region of the IgG molecule implicated in regulation of murine immunoglobulin metabolism (7, 8).

An animal model of antibody clearance is an important first step to probing the catabolic behavior of human antibodies. Nonetheless, one must interpret the results in this heterologous system with some degree of caution because it is possible that human immunoglobulins may not interact appropriately with the putative mouse receptors. For example, in man, the IgG subclasses have half-lives of approximately 25 days, with the exception of IgG₃, which has a half-life of 7 days (12). In the SCID mouse, both IgG₃ and IgG₄ are noted to have shorter half-lives than IgG₁ and IgG₂ (10), suggesting that the regulation of the intravascular metabolism of the human isotypes is, at best, only partially reflected in the mouse model. Nonetheless, preservation of the concentration-catabolism phenomenon, a unique feature of IgG metabolism (12, 13), does speak for some fidelity to normal catabolic pathways.

As a general rule, previous work defining the structural correlates of antibody functional behavior have associated various attributes with specific loci on the molecule. For example, complement binding occurs on an exposed face of the C_{H2} domain (15), whereas hinge-proximal sequences in C_{H2} have been associated with binding to the human Fc γ RI receptor (22). In contrast, the present investigation suggests that all three regions contribute incrementally to the overall rate of catabolism. The C_{H2} - C_{H3} domain interface, which interacts with the putative "Brambell" receptor mentioned above (17-19), has been demonstrated to be of importance in regulating metabolism of IgG₁ in mice (7, 8). Our findings do not contradict this conclusion, but instead emphasize that multiple regions are likely involved in the regulation of immunoglobulin half-life, either exerting their effects by conformational changes on the C_{H2} and C_{H3} regions, altered susceptibility to proteolysis, or possibly by additional receptor interactions that have yet to be elucidated. A previous study of intrinsically labeled mutant murine immunoglobulin with hybrid heavy chains (23) has shown that the determinant of subclass-specific catabolic rate in mice resides in the COOH-terminal end of the C_{H2} and in the C_{H3} domain, paralleling the conclusions of Kim *et al.* (7, 8). A further conclusion of that study, consistent with the present observation, is that deletion of any of the constant domains of IgG_{2b} results in the shortening of intravascular half-life either directly or by inducing conformational changes elsewhere in the molecule (23).

HALF-LIFE OF CHIMERIC ANTIBODIES

A provocative finding with the γ_1/γ_4 panel of antibodies is the prolonged half-life of the γ_4/γ_1 recombinant molecule, consistently observed with different preparations of antibodies and differing sources of SCID mice (data not shown). Because binding by the putative "Brambell" receptor, FcRn, is influenced by sequences in the C μ 2 region (7, 8), it may not be surprising that an intradomain mutation in this region would have a profound effect on antibody clearance. It, however, remains unexplained exactly how these changes lead to prolongation of half-life. Possibly the 4-4-4/1-1 antibody has a higher affinity for the protective receptor than either IgG $_1$ or IgG $_4$. To our knowledge, binding constants for the interaction of human constant regions with murine FcRn have not been determined. Alternatively, the increased half-life could originate from a change in the number of normal regulatory regions on the immunoglobulin molecule (a "dosage" effect), or may instead reflect a novel mechanism, possibly through conformational changes or additional interactions with a specific receptor.

The presently described whole-body half-lives of the wild-type immunoglobulins are similar to the immunoglobulin whole-body half-life values described for SCID mice in our initial study, ranging between 8% and 18% higher than initially described, and in the same relative rank order (10). This minor difference is within the range of intragroup variation typically noted on measurements performed on different occasions, possibly related to variation in animal size, metabolic rate, and other environmental factors. Our measurements may also be compared with those of other investigators who have measured the clearance of specific immunoglobulins in SCID mice, by differing methods. Bazin *et al.* (24), using immunological means, found that the serum half-life of an IgG $_2$ antihuman Rh(D) antibody in SCID mice was 6.3 ± 0.5 days. Hassan *et al.* (25), assaying by sandwich ELISA, demonstrated that human donor and mouse-human chimeric IgG $_2$ had serum half-lives of approximately 7 days in SCID mice. Although these values are longer than those noted in our present and previous studies (10), variation in apparent immunoglobulin half-life based on the method of assay is a well known phenomenon (12, 13) and is a possible cause of the difference in results. In contrast to the various techniques of assaying serum by immunological means, we have used whole-body measurements of iodinated proteins, because it avoids perturbation of the intravascular pool by periodic bleeding, which can artifactually affect the apparent clearance rate. In concordance with our findings, Bazin *et al.* (24) and Hassan *et al.* (25) demonstrated that injection of human serum resulted in an accelerated clearance of IgG $_2$ (concentration-catabolism phenomenon).

In summary, we have shown that all three of the constant region domains have an incremental effect on the half-life of IgG $_2$ and IgG $_3$. This effect may, in fact, be mediated by interaction of a single region of the immunoglobulin molecule with a specific receptor, as suggested by Kim *et al.* (7, 8), with conformational effects on the receptor binding site mediated by the other regions of the immunoglobulin molecule. The hybrid γ_4/γ_1 molecule, with a half-life greater than either parental immunoglobulin, raises interesting possibilities regarding mechanisms controlling immunoglobulin metabolism. Additional studies of selected immunoglobulins bearing single amino acid changes will define the relationship between the affinity for FcRn and

the observed serum half-life and may suggest additional elements that regulate *in vivo* half-life. Understanding the mechanisms and pathways of antibody clearance will result in the ability to produce immunoglobulins with improved pharmacokinetic properties.

REFERENCES

1. Zuckier, L. S., and DeNardo, G. L. Trials and tribulations: oncological antibody imaging comes to the fore. *Semin. Nucl. Med.*, 27: 10-29, 1997.
2. F-D-C Reports, Inc. The NDA pipeline-1996. Chevy Chase, MD: F-D-C Reports, Inc., 1997.
3. Hand, P. H., Kashmini, S. V. S., and Schlom, J. Potential for recombinant immunoglobulin constructs in the management of carcinoma. *Cancer (Phila.)*, 73 (Suppl. 3): 1105-1113, 1994.
4. Morrison, S. L., Johanson, M. J., Herzenberg, L. A., and Oi, V. T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. *Proc. Natl. Acad. Sci. USA*, 81: 6851-6855, 1984.
5. Winter, G., and Milstein, C. Man-made antibodies. *Nature (Lond.)*, 349: 293-299, 1991.
6. Wright, A., Shin, S.-U., and Morrison, S. L. Genetically engineered antibodies: progress and prospects. *Crit. Rev. Immunol.*, 12: 125-168, 1992.
7. Kim, J.-K., Tsen, M.-F., Ghetie, V., and Ward, E. S. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. *Eur. J. Immunol.*, 24: 542-548, 1994.
8. Kim, J. K., Tsen, M. F., Ghetie, V., and Ward, E. S. Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice. *Scand. J. Immunol.*, 40: 457-465, 1994.
9. Jungbans, R. P. Finally, The Brambell receptor (FcRn). Mediator of transmission of immunity and protection from catabolism for IgG. *Immunol. Res.*, 16: 29-57, 1997.
10. Zuckier, L. S., Georgescu, L., Chang, C. J., Scharff, M. D., and Morrison, S. L. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. *Cancer (Phila.)*, 73 (Suppl. 3): 794-799, 1994.
11. Bosma, G. C., Custer, R. P., and Bosma, M. J. A severe combined immunodeficiency mutation in the mouse. *Nature (Lond.)*, 301: 527-530, 1983.
12. Zuckier, L. S., Rodriguez, L. D., and Scharff, M. D. Immunologic and pharmacologic concepts of monoclonal antibodies. *Semin. Nucl. Med.*, 19: 166-186, 1989.
13. Waldmann, T. A., and Strober, W. Metabolism of immunoglobulins. *Prog. Allergy*, 13: 1-110, 1969.
14. Canfield, S. M., and Morrison, S. L. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the C μ 2 domain and is modulated by the hinge region. *J. Exp. Med.*, 173: 1483-1491, 1991.
15. Tao, M. H., Canfield, S. M., and Morrison, S. L. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the C μ 2 domain. *J. Exp. Med.*, 173: 1025-1028, 1991.
16. Fraker, P. J., and Speck, J. C., Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycylurea. *Biochem. Biophys. Res. Commun.*, 80: 849-857, 1978.
17. Ghetie, V., Hubbard, J. G., Kim, T. K., Tsen, M. F., Lee, Y., and Ward, E. S. Abnormally short serum half-lives of IgG in β 2-microglobulin-deficient mice. *Eur. J. Immunol.*, 26: 690-696, 1996.
18. Israel, E. J., Wilsker, D. F., Hayes, K. C., Schoenfeld, D., and Simister, N. B. Increased clearance of IgG in mice that lack β 2-microglobulin: possible protective role of FcRn. *Immunology*, 89: 573-578, 1996.
19. Brambell, F. W. R., Hemmings, W. A., and Morris, I. G. A theoretical model of γ -globulin catabolism. *Nature (Lond.)*, 203: 1352-1355, 1964.
20. Brambell, F. W. R. The transmission of immunity from mother to young and the catabolism of immunoglobulins. *Lancet*, 2: 1087-1093, 1966.
21. Duncan, A. R., Woolf, J. M., Purtridge, L. J., Burton, D. R., and Winter, G. Localization of the binding site for the human high-affinity Fc receptor on IgG. *Nature (Lond.)*, 332: 563-564, 1988.
22. Pollock, R. R., Franch, D. L., Metlay, J. P., Birshtein, B. K., and Scharff, M. D. Intravascular metabolism of normal and mutant mouse immunoglobulin molecules. *Eur. J. Immunol.*, 20: 2021-2027, 1990.
23. Bazin, R., Boucher, G., Monier, G., Chevrier, M.-C., Verreze, S., Broly, H., and Lemieux, R. Use of hu-IgG-SCID mice to evaluate the *in vivo* stability of human monoclonal IgG antibodies. *J. Immunol. Methods*, 172: 209-217, 1994.
24. Hassan, M. S., Abedi-Valgerdi, M., Lefranc, G., Hammarstrom, L., and Smith, C. I. E. Biological half-life of normal and truncated human IgG $_2$ in acid mice. *Eur. J. Immunol.*, 21: 1319-1322, 1991.



Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

THE MARCH

Coming Together To Conquer Cancer
September 25 & 26
Washington, D.C.



Only a national, grassroots demonstration of strong support can assure that we can accelerate progress against this disease. Please join **the March!**

Webster K. Givens, PhD
President, AACR

Notice to Members of the American Association for Cancer Research (AACR)

Officers for 1998-1999

President: Webster K. Cavenee, Ludwig Institute for Cancer Research, La Jolla, CA 92093-0660

President-Elect: Daniel D. Von Hoff, Institute for Drug Development, San Antonio, TX 78245

Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483

Annual Dues

The annual dues of active members of the AACR are \$175, \$90 of which may be applied to a subscription to *Cancer Research*. Corresponding members of the Association will be charged an appropriate fee to offset postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to: Member Services, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300; FAX: (215) 440-9313.

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal *Cancer Research* may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202 (Telephone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588). As long as supplies permit, single copies of *Cancer Research* will be sold at \$30 per copy for regular and Supplement issues, plus \$4 shipping for orders outside the U.S. The annual *Proceedings of the American Association for Cancer Research* is available at \$45 per copy, plus \$6 shipping for orders outside the U.S.

Advertisements in *Cancer Research*

Advertisement insertion orders and copy must be received approximately 5 weeks prior to the date of the issue in which the advertisement is to be published. The journal is mailed approximately 5 days preceding the date of issue. Inquiries about advertising should be directed to: M. I. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009 (Telephone: (609) 768-9360; FAX: (609) 753-0064).

Historical Cover Themes

Readers are invited to submit themes (events, persons, institutions) for consideration for the illustrated covers of *Cancer Research*. Correspondence regarding suggested cover themes, or other matters regarding covers, should be addressed to the Cover Editor, AACR Publications Department.

Submission of Manuscripts

Manuscripts should be sent to the attention of: Dr. Carlo M. Croce, Editor-in-Chief, AACR Publications Department, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. If accepted, they will be listed under one of ten categories in the Table of Contents. Please specify in a covering letter which category applies to your submission: biochemistry and biophysics, carcinogenesis, clinical investigations, endocrinology, epidemiology and prevention, experimental therapeutics, immunology, molecular biology and genetics, tumor biology, and virology. (Final categorization in the Table of Contents is at the discretion of the Editor-in-Chief.) For other submission requirements, consult the "Instructions for Authors" printed in the January 1 issue of the journal and available through the AACR Website at <http://www.aacr.org/caninst.htm>. Reprints of the "Instructions" are available also upon request.

Manuscript Processing Fee

Journal policy requires that a manuscript processing fee of \$75 be assessed for each paper to defray the expenses incurred in the editorial review process. Each manuscript submitted for publication should be accompanied by a check (drawn on a U.S. bank) for \$75 in U. S. currency, payable to AACR, Inc., or credit card information (VISA, Mastercard, or American Express) should be supplied. Note: If an author resubmits a manuscript that our Editors previously found unacceptable for publication, it is journal policy to consider it a new submission, assign it a new manuscript number, and charge the author another \$75 handling fee to cover the cost of review.

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of \$80 per printed page. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Carlo M. Croce, Editor-in-Chief, at the time of submission, for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Copyright and Copyright Clearance Center

The Copyright Revision Act (PL 94-553), which became effective January 1, 1978, states that the copyright of a work is vested in the author from the moment of creation. Therefore, all authors who wish to publish in *Cancer Research* must formally transfer copyright to the proprietor of the journal, AACR, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U. S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. However, it is necessary for these authors to sign the appropriate section of the transfer form. In the case of articles supported by federal grants or contracts, copyright transfer to AACR, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

Copies of articles for which AACR, Inc. owns the copyright may be made for personal or internal use, provided that the copier pay the per-copy fee of \$4 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978. Those who wish to photocopy *Cancer Research* articles may report the number of copies they have made, together with the fee code 0008-5472/98 \$04.00, to: Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923; (508) 750-8400. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

Between June 1978 and August 1983, a fee code appeared on the first page of all articles for which *Cancer Research* owned the copyright. For those issues, it is understood that any articles which did not carry this code are in the public domain.

Cancer Research is abstracted or indexed in Biological Abstracts, Chemical Abstracts, Index Medicus, MEDLINE, Current Contents, and Reference Update. This journal is printed on acid-free paper.

No responsibility is accepted by the Editors, by AACR, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Cancer Research (ISSN 0008-5472) is published twice a month by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for \$90 annually for members and \$495 for individual nonmembers. *Cancer Research* is only available to institutions as a combined subscription with *Clinical Cancer Research*. The combined 1998 institutional subscription price of \$795 includes a subscription to *Clinical Cancer Research*. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copyright 1998 by the American Association for Cancer Research, Inc. Printed in the U.S.A.